Home >
News >
#ESHCML2023 PROGRAM HIGHLIGHT: WORKSHOP ON SINGLE CELL ANALYSIS
#ESHCML2023 PROGRAM HIGHLIGHT: WORKSHOP ON SINGLE CELL ANALYSIS
June 14, 2023
25th ANNUAL JOHN GOLDMAN CONFERENCE ON
CHRONIC MYELOID LEUKEMIA:
BIOLOGY AND THERAPY
October 6-8, 2023
Mandelieu-La Napoule, France - #ESHCML2023
Co-organizers: Ravi Bhatia, Tim Brümmendorf, Mhairi Copland, Michael Deininger, Olivier Hantschel, Vignir Helgason, Sin Tiong Ong, Jerry Radich, Delphine Réa
Advisory Committee: Jane Apperley, Susan Branford, Carlo Gambacorti-Passerini, François Guilhot, Rüdiger Hehlmann, Pierre Laneuville, Danilo Perrotti, Giuseppe Saglio, Charles Schiffer, Simona Soverini, Peter Valent, Rick Van Etten
One of the main highlights of the #ESHCML2023 program is the
WORKSHOP FOR NON-CLINICAL SCIENTISTS #2: SINGLE CELL ANALYSIS
Chairs: Mhairi Copland (Glasgow) & Sin Tiong Ong (Singapore)
Single cell technologies to explore the role of ageing in cancer
by Kristina Kirschner (Glasgow)
Mass cytometry for assessment of response to therapy in leukemia
by Bjorn Tore Gjertsen (Bergen)
New insights into human diseases using single cell atlases
by Shyam Prabhakar (Singapore)
Sunday, October 8, 2023 / 09:00 - 11:00 CEST
ABOUT THE CONFERENCE
The program includes the latest in research in chronic myeloid leukemia, including basic, translational and clinical research with an emphasis on open discussion among participants. There are also scientific workshops to discuss the latest technologies of value in CML research, and clinical symposia with focus on topics of interest to the CML community. There are special lectures on topics of general interest to the CML community from lead experts in their field. The program is designed to encourage discussion and collaboration among participants, presenters and attendees.
The program will be of interest to:
- Junior and senior biologists and clinicians (MD, PhD, MD-PhD)
- Residents and biologists still in-training
- Physicians and other healthcare providers managing patients with CML
- Researchers with interest in hematologic malignancies and myeloproliferative neoplasms in general,
and CML in particular
MORE INFORMATION